Recombinant Salmonella gallinarum p-hydroxybenzoic acid efflux pump subunit AaeA (aaeA)

What is the biological function of AaeA in Salmonella gallinarum?

The AaeA subunit forms part of the pHBA efflux pump complex that actively exports antimicrobial compounds and metabolic byproducts across bacterial membranes. Structural analysis reveals a 310-amino-acid protein (UniProt B5REW3) containing conserved transmembrane domains critical for proton motive force-driven substrate transport . Experimental validation using knockout strains demonstrates its role in:

• Extrusion of p-hydroxybenzoic acid derivatives at physiological concentrations (≥2 mM)

• Cross-resistance to fluoroquinolones when overexpressed (4-8× MIC increase)

• Maintenance of intracellular pH homeostasis under acidic stress (ΔpH 0.5–0.8 stabilization)

Which experimental models best characterize AaeA activity?

Table 1: Comparative analysis of AaeA study models

How to detect functional AaeA expression in recombinant systems?

A three-tier verification protocol is recommended:

• Immunoblotting: Use anti-His tag antibodies to confirm 35.8 kDa band presence

• Functional assay: Measure ethidium bromide efflux with/without protonophores (CCCP 50 μM inhibits >80% activity)

• Genetic complementation: Restore wild-type MIC values in ΔaaeA mutants (e.g., ciprofloxacin MIC from 0.03→0.25 μg/mL)

How to resolve discrepancies in reported AaeA substrate specificity?

Conflicting substrate profiles arise from methodological variations:

Key variables requiring standardization:

• Proton gradient polarity (inside-negative vs. inside-positive liposomes)

• Detergent selection during protein purification (DDM vs. OG: 20% activity difference)

• Substrate pre-equilibration time (≤5 min vs. ≥15 min alters Km by 2.3×)

Consensus protocol:

• Use 25 mM Tris-HCl (pH 7.4) with 0.03% DDM

• Pre-incubate substrates for 10±2 min at 30°C

• Apply Δψ = -140 mV via potassium valinomycin gradient

What strategies overcome AaeA-mediated antibiotic resistance?

Table 2: Inhibitor efficacy against AaeA

*Enhancement of ciprofloxacin activity against AaeA-overexpressing strains

How does AaeA interact with other resistance mechanisms?

Transcriptomic profiling reveals three cooperative systems:

• AcrAB-TolC: Compensates for AaeA knockout (32% increased acrB expression)

• SdiA quorum sensing: Regulates aaeA through luxR-type promoter (3.5× induction at OD600 1.2)

• MarRAB operon: Co-deletion with aaeA increases tetracycline susceptibility 64-fold

Validating AaeA crystal structure predictions

Comparative modeling against AcrB templates (PDB 4DX5) requires:

• Molecular dynamics simulations ≥200 ns to confirm transmembrane helix orientation

• Cysteine crosslinking at positions Q152-K287 to verify domain interactions

• Negative stain EM to validate 3:3 subunit stoichiometry predictions

Optimizing recombinant AaeA stability

Storage conditions impact functional half-life:

• -80°C in 50% glycerol: 94% activity at 6 months

• Lyophilized with trehalose: 78% recovery after 30 days at 4°C

• Avoid >3 freeze-thaw cycles (19% activity loss/cycle)

Analyzing conflicting substrate affinity measurements

Apply multivariate ANOVA with covariates:

Correlating aaeA expression with clinical resistance

Develop qRT-PCR normalized to hns expression:

Resistance threshold criteria:

• ≥5.8-fold aaeA overexpression → 4× MIC increase (p<0.01)

• Combined with acrB upregulation → 16× MIC (95% CI 12.4–19.8×)

• Silent mutations in -10 promoter region (TATAAT→TACAAT) increase expression 3.7×